Vaxcyte (NASDAQ:PCVX) Given “Buy” Rating at Guggenheim

Vaxcyte (NASDAQ:PCVX)‘s stock had its “buy” rating restated by investment analysts at Guggenheim in a research report issued on Wednesday,Benzinga reports. They currently have a $160.00 price target on the stock. Guggenheim’s price target suggests a potential upside of 119.61% from the company’s previous close.

A number of other equities research analysts have also issued reports on the company. The Goldman Sachs Group assumed coverage on Vaxcyte in a research note on Friday, December 20th. They issued a “buy” rating and a $135.00 target price on the stock. Needham & Company LLC restated a “buy” rating and issued a $140.00 price objective on shares of Vaxcyte in a research report on Wednesday, February 26th. Nine analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $147.50.

Vaxcyte Trading Up 4.3 %

Shares of NASDAQ:PCVX traded up $3.01 during midday trading on Wednesday, hitting $72.86. 74,242 shares of the stock were exchanged, compared to its average volume of 1,165,805. Vaxcyte has a twelve month low of $58.10 and a twelve month high of $121.06. The company has a 50 day moving average price of $82.82 and a 200-day moving average price of $94.59. The stock has a market cap of $9.38 billion, a P/E ratio of -15.84 and a beta of 1.02.

Vaxcyte (NASDAQ:PCVX) last announced its earnings results on Tuesday, February 25th. The company reported ($1.02) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.16) by $0.14. On average, equities research analysts expect that Vaxcyte will post -4.21 earnings per share for the current year.

Insiders Place Their Bets

In other Vaxcyte news, Director Teri Loxam sold 6,250 shares of Vaxcyte stock in a transaction dated Wednesday, January 15th. The stock was sold at an average price of $85.11, for a total value of $531,937.50. Following the completion of the sale, the director now owns 7,175 shares in the company, valued at $610,664.25. The trade was a 46.55 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO Andrew Guggenhime sold 8,000 shares of the company’s stock in a transaction dated Wednesday, December 18th. The shares were sold at an average price of $88.78, for a total transaction of $710,240.00. Following the transaction, the chief financial officer now directly owns 109,491 shares of the company’s stock, valued at approximately $9,720,610.98. This represents a 6.81 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 54,250 shares of company stock valued at $4,550,258 in the last quarter. 3.10% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Vaxcyte

A number of institutional investors have recently bought and sold shares of PCVX. Universal Beteiligungs und Servicegesellschaft mbH purchased a new position in Vaxcyte during the fourth quarter worth approximately $8,487,000. Forum Financial Management LP acquired a new stake in shares of Vaxcyte during the 4th quarter worth $255,000. GF Fund Management CO. LTD. purchased a new position in shares of Vaxcyte in the 4th quarter worth $214,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in Vaxcyte by 15.8% in the fourth quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 472,964 shares of the company’s stock valued at $38,717,000 after acquiring an additional 64,690 shares during the last quarter. Finally, Windsor Advisory Group LLC grew its position in Vaxcyte by 72.5% during the fourth quarter. Windsor Advisory Group LLC now owns 39,223 shares of the company’s stock valued at $3,211,000 after acquiring an additional 16,479 shares during the period. 96.78% of the stock is currently owned by hedge funds and other institutional investors.

About Vaxcyte

Vaxcyte, Inc, a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine for the prevention of invasive pneumococcal disease. The company also develops VAX-31 to protect against emerging strains and to help address antibiotic resistance; VAX-A1, a novel conjugate vaccine candidate to prevent disease caused by Group A Streptococcus; VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis; and VAX-GI to prevent Shigella, a bacterial illness.